Add office photos
Employer?
Claim Account for FREE
DIVI'S Laboratories
3.7
based on 1.4k Reviews
Video summary
Company Overview
Company Locations
Working at DIVI'S Laboratories
Company Summary
DIVI'S Laboratories is a major player in the global API market, focusing on high-quality active pharmaceutical ingredients for various international markets.
Overall Rating
3.7/5
based on 1.4k reviews
5% below
industry average
Highly rated for
Job security
Critically rated for
Work satisfaction, Promotions, Company culture
Work Policy
Work from office
90% employees reported
Rotational Shift
45% employees reported
Strict timing
60% employees reported
No travel
57% employees reported
View detailed work policy
Top Employees Benefits
Free meal
95 employees reported
Job/Soft skill training
87 employees reported
Health insurance
63 employees reported
Office gym
28 employees reported
View all benefits
About DIVI'S Laboratories
Founded in1990 (35 yrs old)
India Employee Count5k-10k
Global Employee Count10k-50k
India HeadquartersHyderabad/Secunderabad, Telangana, India
Office Locations
--
Websitedivislabs.com
Primary Industry
Other Industries
--
Are you managing DIVI'S Laboratories's employer brand? To edit company information,
claim this page for free
View in video summary
Divi’s Laboratories Limited is one of the largest API companies in the world, with ~$730M in revenue and exporting to more than 95 countries.
Mission: To be a good corporate citizen and not only add value in our core competency areas of Pharma but also serve the community at large through social, educational and environmental initiatives that would establish strong foundations for a better tomorrow.
Vision: To maintain leadership in custom synthesis of APIs and Intermediates for health care and life sciences industry and to be one of the top companies world-wide in the domain. To develop generic APIs for the late life cycle needs of the Industry.
Managing your company's employer brand?
Claim this Company Page for FREE
DIVI'S Laboratories Ratings
based on 1.4k reviews
Overall Rating
3.7/5
How AmbitionBox ratings work?
5
495
4
428
3
242
2
69
1
142
Category Ratings
4.0
Job security
3.6
Salary
3.5
Skill development
3.4
Work-life balance
3.3
Company culture
3.2
Promotions
3.2
Work satisfaction
DIVI'S Laboratories is rated 3.7 out of 5 stars on AmbitionBox, based on 1.4k company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at DIVI'S Laboratories
based on 1.3k reviews
3.9
Rated by 155 Women
Rated 4.1 for Job security and 3.7 for Skill development
3.7
Rated by 1.1k Men
Rated 3.9 for Job security and 3.6 for Salary
Work Policy at DIVI'S Laboratories
based on 118 reviews in last 6 months
Work from office
90%
Permanent work from home
6%
Hybrid
4%
DIVI'S Laboratories Reviews
Top mentions in DIVI'S Laboratories Reviews
+ 5 more
HCLTech
Workplace transformation starts with you
Explore various roles and find your spark with us
Compare DIVI'S Laboratories with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 3.7/5 based on 1.4k reviews | 4.0/5 based on 5.8k reviews  | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Job security | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Promotions Work satisfaction Company culture |  No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 90% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 3.9 Good rated by 155 women | 4.0 Good rated by 442 women | 4.1 Good rated by 681 women | - no rating available |
Rating by Men Employees | 3.7 Good rated by 1.1k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 4.0 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
DIVI'S Laboratories Salaries
DIVI'S Laboratories salaries have received with an average score of 3.6 out of 5 by 1.4k employees.
Chemist
(796 salaries)
Unlock
₹1.2 L/yr - ₹5.6 L/yr
Production Chemist
(535 salaries)
Unlock
₹1.2 L/yr - ₹5.7 L/yr
Supervisor
(503 salaries)
Unlock
₹1 L/yr - ₹5.5 L/yr
Analyst
(370 salaries)
Unlock
₹1.7 L/yr - ₹7 L/yr
Production Supervisor
(340 salaries)
Unlock
₹1.2 L/yr - ₹5.5 L/yr
Maintenance Engineer
(160 salaries)
Unlock
₹1.5 L/yr - ₹6.2 L/yr
Quality Analyst
(147 salaries)
Unlock
₹1.8 L/yr - ₹5.3 L/yr
Maintenance Supervisor
(132 salaries)
Unlock
₹1.9 L/yr - ₹5.4 L/yr
QC Analyst
(130 salaries)
Unlock
₹1.9 L/yr - ₹5.6 L/yr
Quality Control Analyst
(102 salaries)
Unlock
₹1.9 L/yr - ₹4.3 L/yr
DIVI'S Laboratories Interview Questions
Interview questions by designation
Top DIVI'S Laboratories interview questions and answers
Get interview-ready with top interview questions
DIVI'S Laboratories Jobs
Popular Designations DIVI'S Laboratories Hires for
Chartered Accountant
Create job alerts
Junior Engineer
Create job alerts
QC Analyst
Create job alerts
Autocad Draughtsman
Create job alerts
Popular Skills DIVI'S Laboratories Hires for
Current Openings
DIVI'S Laboratories News
View all
Gland Pharma Share Price Target 2025 2026 to 2030
- Hyderabad-based pharmaceutical company Gland Pharma supplies injectables to over sixty countries.
- Gland Pharma shares have seen both short-term and long-term investors, and the stock's performance is under close observation.
- The Gland Pharma Share Price Target for 2025 is predicted to be between INR 1,813 to INR 2,827.
- From 2026 to 2030, Gland Pharma's share price target is projected at a minimum of INR 2,318 and a maximum of INR 6,680.08 in 2030.
- Gland Pharma's competitors include Sun Pharma, CIPLA, Divis Labs, and Dr. Reddys Labs.
- Gland Pharma's share price history isn't very long, having been listed on the National Stock Exchange in 2020.
- On August 13th, 2021, the GLAND NSE stock hit its highest point of INR 4,287.
- Consulting expert advice for the stock market predictions is advisable, as the values provided in the article are based on predictions and may not be accurate.
- Investors would need to consider verified information from other sources to make informed decisions about their investments.
- The article includes the projected maximum and minimum prices for Gland Pharma share for every month in 2025 and year-wise projection for 2026 to 2030.
VIE Stories | 10 Feb, 2025
Q3 Results Live: Power Grid, Tata Chemicals, Premier Energies, Religare To Report Earnings Today
- A total of 104 companies will declare their financial results for the October-December quarter on Monday.
- Tata Chemicals, Power Grid Corp., Divi's Laboratories, Aditya Birla Capital, and General Insurance Corp. are the major companies announcing their Q3 results today.
- Aditya Birla Capital Ltd., Doms Industries Ltd., Thomas Cook (India) Ltd., Premier Energies Ltd., and Religare Enterprises will be the other companies reporting their earnings on Monday.
- Comprehensive LIVE Coverage Of Budget 2025, Income Tax News, Stock Market Updates, Business Action & Latest News. Catch All The Action Also on NDTV Profit LIVE TV.
Bloomberg Quint | 3 Feb, 2025
Stock Market Today: All You Need To Know Going Into Trade On Feb. 3
- US stocks ended lower on Friday after the White House asserted that President Donald Trump plans to impose import duties on China, Mexico and Canada over the weekend.
- The greenback notched its best week since November with the Dollar Index rising 0.4%.
- The NSE Nifty 50 and the BSE Sensex ended the Budget day on a muted note as traders assessed the impact of announcements made by Finance Minister Nirmala Sitharaman.
- Foreign portfolio investors stayed net sellers of Indian equities for the 22nd straight session as they sold stocks worth Rs 1,327 crore.
- Domestic institutional investors were net buyers for the 33rd consecutive session as they mopped up equities worth Rs 824 crore.
- Major earnings to look out for include Divi's Laboratories, Tata Chemicals, KEC International, Gland Pharma, and Garden Reach Shipbuilders.
- Stocks to watch: Hero MotoCorp, Lupin, Coal India, Eicher Motors, KEI Industries, MOIL, Indian Bank, Globus Spirits, Quess Corp, Happient Minds Technologies, Vinati Organics.
- In bulk deals, Amazon sold 0.5% shares of Quess Corp.
- Nifty February futures fell 0.25% at a premium of 73 points.
- The Indian rupee closed flat against the US dollar on Friday at 86.62.
Bloomberg Quint | 3 Feb, 2025
Divi's Labs, Tata Chemicals, Power Grid Q3 Results Today — Earnings Estimates
- Divi's Laboratories Ltd., Garden Reach Shipbuilders & Engineers Ltd., Power Grid Corp., Tata Chemicals Ltd., and Welspun Enterprises Ltd. will be among the big companies announcing their Q3 earnings today.
- Divi's Laboratories is expected to report a profit of Rs 500 crore for the quarter ended December.
- Garden Reach Shipbuilders is likely to report a net profit of Rs 115 crore, with revenue worth Rs 1,324 crore.
- Power Grid Corp. is estimated to announce a profit of Rs 4,031 crore, while Tata Chemicals is expected to post a net profit of Rs 191 crore.
Bloomberg Quint | 3 Feb, 2025
Q3 Results Today: Power Grid, Garden Reach Shipbuilders, Tata Chemicals Among 100+ Firms To Declare Earnings
- Over 100 companies, including Power Grid, Garden Reach Shipbuilders, and Tata Chemicals, are set to declare their Q3 results on Feb. 3.
- Tata Chemicals, Divi's Laboratories, Aditya Birla Capital, and General Insurance Corp. are among the major companies announcing their earnings today.
- Some of the biggest names from India’s performing sectors will showcase their earnings for the October-December quarter.
- Companies such as Linc Ltd., Panasonic Energy India, Religare Enterprises Ltd., and Dredging Corporation of India Ltd. are also expected to declare their earnings today.
- Power Grid Corporation of India posted flat net profit and revenues in the quarter ended September.
- Divi’s Laboratories Q2 revenue increased 22.5% year-on-year to Rs2,338 crore.
- Tata Chemicals reported a 46% decline in its net profit YoY to Rs 267 crore in its Q2 results.
- Quarterly earnings report will be watched closely by investors as they assess the Q3 performance of companies.
- Premier Energies, Welspun Enterprises, and Doms Industries will also announce their financial results on Feb. 3.
- Aditya Birla Capital, Bomb ay Dyeing, Bannari Amman Sugars and Alembic Pharmaceuticals also among other companies announcing their earnings today.
Bloomberg Quint | 3 Feb, 2025
Divi's Labs Starts Commercial Operations At Kakinada Greenfield Project
- Divi's Laboratories has started commercial operations at its Kakinada plant in Andhra Pradesh.
- The first phase of the project is being implemented on 200 acres of the 500-acre Unit III site, with an estimated investment between Rs 1,200 crores to Rs 1,500 crore.
- Divi's Labs currently operates two manufacturing sites near Hyderabad and Visakhapatnam, making it one of the largest active pharmaceutical ingredients manufacturing facilities in the world.
- The company reported a strong performance in the second quarter, with a 22.5% increase in consolidated revenue and a significant rise in net profit.
Bloomberg Quint | 2 Jan, 2025
F&O Strategy: Divi’s Lab; Bull call spread
- Immediate support levels for the stock are at ₹5,750 and ₹5,423.
- If the stock manages to close above ₹5,950, it has the potential to reach a new high.
- Divi’s Lab witnessed a healthy rollover of 31% to January series.
- Consider a bull-call spread strategy using January options with a net cost of ₹4,315.
HinduBusinessLine | 21 Dec, 2024
Divi's Lab Clarifies After US Court Paves Way For Novartis' Heart Drug Generic; Share Price Down
- Divi's Laboratories' shares fell over 3% as a US court dismissed Novartis AG's bid to block the launch of a generic version of its heart drug Entresto.
- Divi's Labs has a contract manufacturing organisation pact with Novartis for Entresto.
- The launch of the generic drug by MSN Pharmaceuticals is expected to impact the market share of Entresto.
- Divi's Labs clarified that it sees no material impact from this news.
Bloomberg Quint | 5 Dec, 2024
Five Stocks To Buy: How To Trade Balrampur Chini, Divi's Lab, Skipper, Orient Cement, Crompton
- Analysts have shared 'buy' calls on shares of Balrampur Chini Mills, Divis Laboratories, Skipper, Orient Cement, and Crompton Greaves Consumer Electricals.
- Balrampur Chini Mills: The stock should be bought at Rs 585 with a target price of Rs 610 and stop loss of Rs 585.
- Divis Laboratories: Buy shares at a target price of Rs 6,550 and a stop loss of Rs 6,050.
- Skipper: Buy shares at Rs 578 with a target price range of Rs 618 to 630 and a stop loss at Rs 560.
- Orient Cement: Buy shares at Rs 342 with a target price of Rs 364 and a stop loss of Rs 332.
- Crompton: Buy shares at Rs 409 with a target price range of Rs 432 and a stop loss at Rs 398.
Bloomberg Quint | 2 Dec, 2024
Broker’s call: Divi’s Lab (Sell)
- Divi’s Laboratories reported better-than-expected Q2FY24 revenue, but lower EBITDA margin.
- Revenue was 8% ahead of estimates and EBITDA 6% ahead.
- Management suggests revenue growth came from custom synthesis, while generics face pricing pressures.
- The stock is overhyped due to the BioSecure Act; sell rating with a target price of ₹3,890.
HinduBusinessLine | 11 Nov, 2024
Powered by
DIVI'S Laboratories Offices
Compare DIVI'S Laboratories with
Biocon Limited
3.9
Zydus Lifesciences
4.1
Glenmark Pharmaceuticals
3.9
Torrent Pharmaceuticals
3.9
Lupin
4.2
Aurobindo Pharma
4.0
Piramal Group
3.9
Dr. Reddy's
4.0
Alembic Pharmaceuticals
4.0
Abbott
4.1
Alkem Laboratories
3.9
Ipca Laboratories
3.9
Ajanta Pharma
4.1
Akums Drugs & Pharmaceuticals Limited
4.4
Cadila Pharmaceuticals
3.5
Pfizer
4.0
Laurus Labs
4.2
Wockhardt
3.9
Granules India
3.8
Sanofi
4.2
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Write a review
Share interview
Contribute salary
Add office photos
Companies Similar to DIVI'S Laboratories
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
Piramal Group
Pharma
3.9
• 1.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.1k reviews
DIVI'S Laboratories FAQs
When was DIVI'S Laboratories founded?
DIVI'S Laboratories was founded in 1990. The company has been operating for 35 years primarily in the Pharma sector.
Where is the DIVI'S Laboratories headquarters located?
DIVI'S Laboratories is headquartered in Hyderabad/Secunderabad, Telangana.
How many employees does DIVI'S Laboratories have in India?
DIVI'S Laboratories currently has more than 9,700+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in DIVI'S Laboratories based on the number of reviews submitted on AmbitionBox.
Does DIVI'S Laboratories have good work-life balance?
DIVI'S Laboratories has a work-life balance rating of 3.4 out of 5 based on 1,300+ employee reviews on AmbitionBox. 33% employees rated DIVI'S Laboratories 3 or below, while 67% employees rated it 4 or above for work-life balance. This rating suggests that while some employees recognize efforts towards work-life balance, there is scope for improvement based on employee feedback. We encourage you to read DIVI'S Laboratories work-life balance reviews for more details
Is DIVI'S Laboratories good for career growth?
Career growth at DIVI'S Laboratories is rated as moderate, with a promotions and appraisal rating of 3.2. 33% employees rated DIVI'S Laboratories 3 or below, while 67% employees rated it 4 or above on promotions/appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading DIVI'S Laboratories promotions/appraisals reviews for more detailed insights.
What are the pros and cons of working in DIVI'S Laboratories?
Working at DIVI'S Laboratories comes with several advantages and disadvantages. It is highly rated for job security. However, it is poorly rated for work satisfaction, promotions / appraisal and company culture, based on 1,300+ employee reviews on AmbitionBox.
Recently Viewed
PHOTOS
Medanta the Medicity
4 office photos
REVIEWS
Larsen & Toubro Group
No Reviews
REVIEWS
Metso
No Reviews
REVIEWS
Metso
No Reviews
JOBS
Metso
No Jobs
REVIEWS
Metso
No Reviews
REVIEWS
Metso
No Reviews
REVIEWS
Metso
No Reviews
REVIEWS
Metso
No Reviews
COMPANY BENEFITS
Cipla Health
No Benefits
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
